Exocell Inc.

Glycadia Inc.

Margo P Cohen

Clyde W Shearman

Van-Yu Wu

Rex S Clements

Rex Clements

Formulation of long-acting and controlled release preparations of 2-[(3-chlorophenyl)amino] phenylacetic acid (23CPPA) are disclosed. Long-acting preparations comprise a slow-release formulation coated onto a pharmaceutical composition containing 23CPPA, protect against gastric irritation, slow 23CPPA absorption, extend release of 23CPPA, protect against excessively high 23CPPA blood concentrations, and prolong maintenance of blood concentrations of 23CPPA after administration. Controlled release formulations comprise (a) a core element which is a compressed tablet containing a therapeutic dose of 23CPPA and an amount of a solubility modulating substance that controls the release of said 23CPPA in order to provide a therapeutic level over a period of about 24 hours; and (b) on the outer surface of the core element, a sufficient amount of an enteric coating that causes the 23CPPA to release at a rate that permits the use of once-a-day dosing to maintain steady state therapeutic levels of 23CPPA.

Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid

The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

The present invention is directed to the prevention in vivo of the nonenzymatic glycation of albumin, which generates biologically active Amadori glucose adducts in the albumin molecule, as well as methods of using compounds that protect against nonenzymatic glycation in vivo to treat kidney dysfunction.

In vivo methods of treatment to prevent kidney dysfunction using

The present invention is directed to the prevention in vivo of post-secretory Amadori modifications in the Apo B molecule, as well as methods of using compounds that protect against these modifications in vivo to treat hypercholesterolemia and vascular dysfunction.

In Vivo Methods to reduce hypercholesterolemia and improve vascular

This invention deals with genetically engineered immunoglobulins with affinity and specificity for (human) glycated albumin. The invention is directed to the DNA which encodes the immunoglobulins. The DNA sequence can be manipulated to produce chimeras and fragments such as Fab, F(ab').sub.2 or ScFv. The immunoglobulins can be produced by recombinant DNA methods and readily purified. The invention also provides a novel and improved method for treating the complications of diabetes.

Genetically engineered immunoglobulins with specificity for glycated

Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.

Treatment of complications of diabetes with substances reactive with the

An antibody specifically immunoreactive with glycated LDL and methods for using the antibody are provided. The antibody can be used for quantitating amounts of glycated LDL in a sample, for monitoring glycemic control in diabetic patients, for diagnosing disease, for monitoring and diagnosing atherosclerotic cardiovascular disease, and for inhibiting accumulation of LDL cholesterol by cells in tissues subject to atherosclerotic disease.

Monoclonal antibodies against glycated low density lipoprotein

A method of isolating soluble pancreatic islet antigen employs extraction with a non-ionic detergent and fractionation on a gel filtration column. Fractions are screened for high immunoreactivity with diabetic serum which is positive for ICA immunofluorescence when tested on tissue sections of a pancreas from a human blood group O donor. The isolated soluble antigen is suitable for measuring autoantibodies in both complement fixation assays as well as ELISA-type and immunoblotting formats. Methods of using isolated soluble antigen to test serum for autoantibodies are also taught.

Isolation of a soluble 42 KD pancreatic islet cell autoantigen

The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with glycated albumin and insignificantly reactive with other proteins, as well methods of using these monoclonal antibodies to detect glycated albumin.

Monoclonal antibodies against glycated albumin, hybrid cell lines

Monoclonal antibodies specific for an epitope found on hemoglobin glycated both in vivo and in vitro but not found on hemoglobin A.sub.o or hemoglobin A.sub.1c are provided. Use of these antibodies to measure glycohemoglobin levels in the blood provides a measure of the glucose levels in the erythrocyte for the previous 90-120 days. No reduction of the blood sample is required to produce the epitope recognized by the monoclonal antibodies.

Growing community of inventors

New York, NY, United States of America

Margo P Cohen